Published on May 11, 2010
|
May
11, 2010
|
617
832 1113
direct
pbork@foleyhoag.com
|
|
Via
Edgar
|
|
|
Securities
and Exchange Commission
Division
of Corporate Finance
100
F Street, N.E.
Washington,
DC 20549
|
||||
|
Re:
|
Novelos
Therapeutics, Inc.
Registration Statement on Form
S-1
|
|||
Ladies
and Gentlemen:
This
letter constitutes supplemental correspondence on behalf of Novelos
Therapeutics, Inc., a Delaware corporation (the “Company”), related to and filed
together with the Company’s Registration Statement on Form S-1 (the
“Registration Statement”). The Registration Statement
covers the direct offering of up to 60,000,000 shares of the Company’s common
stock, par value $0.00001 per share, by the Company.
Should a
member of the Staff have any questions concerning this filing, it is requested
that he or she contact the undersigned, Paul Bork, at (617) 832-1113, or in my
absence, Matthew Eckert at (617) 832-3057.
|
Very
truly yours,
/s/ Paul
Bork
Paul
Bork
|
PB:vlc
Enclosures
|
Mr.
Harry Palmin
Mr.
Matthew Eckert
|
|
|
|